Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 5, 1998, Pages 473-478

  Salhi, Y ^a   Costagliola, D ^a,h   Rebulla, P ^b   Dessi, C ^c   Karagiorga, M ^d   Lena Russo, D ^e   De Montalembert, M ^f   Girot, R ^g  

^a SORBONNE UNIVERSITÉ   (France)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Dipto Biol Clin Eta Evolutiva   (Italy)

^d AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^e TIMONE HOSPITAL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HÔPITAL TENON   (France)

^h INSERM   (France)

Author keywords

Serum ferritin Desferrioxamine; Thalassemia

Indexed keywords

DEFEROXAMINE; FERRITIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREDICTION; PRIORITY JOURNAL; SEROCONVERSION; STATISTICAL ANALYSIS; THALASSEMIA;

EID: 0032529609     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808150-00009     Document Type: Article

References (21)

1. Salmon-Céron D, Fontbonne A, Saba J, et al Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocysns carinii pneumonia. J Infect Dis 1995;172:656-64.
2. Jacobus DP. Randomization to iron supplementation of patients with advanced human immunodeficiency virus disease-An inadvertent but controlled study with results important for patient care. J Infect Dis 1995;173:1044-5.
3. Weinberg GA. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1996;174:241-2.
4. Boloeart JR, Piette J, Weinberg GA, et al. Iron and oxidative stress as a mechanism for the Enhanced production of human Immunodeficiency virus by alveolar macrophages from otherwise healthy cigarette smokers. J Infect Dis 1996;173:1045-6.
5. Rich EA, Abbud RA. Iron and oxidative stress as a mechanism for The Enhanced production of human Immunodeficiency virus by alveolar macrophages from otherwise healthy cigarette smokers. J Infect Dis 1996;173:1046-7.
6. Costagliola D, De Montalembert M, Lefrère JJ, et al. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. Br J Haematol 1994;87:849-52.
7. Boelaert JR Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996;5.36-46.
8. Worwood M. Serum ferritin. In Jacobs A, Worwood M, eds. Iron in biochemistry and medicine. New York: Academic, 1980:203-44.
9. Ellaurie M, Rubinstein A. Ferritin levels in pediatric HIV-1 infection. Acra Paediatr 1994;83:1035-7.
10. Gupta S, Imam A, Licorish K. Serum ferritin in acquired immune deficiency syndrome. J Clin Lab Immunol 1986;20:11-13.
11. Riera A, Gimferrer E, Cadafalch J, Remacha A, Martin S. Prevalence of high serum and red cell ferritin levels in HIV-infected patients. Haematohgica 1994;79:165-7.
12. Brittenham GM, Griffith PM, Neinhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
13. Schreck R, Rieber P, Bauerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 1991;10:2247-58.
14. Staal FJT, Roederer M, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kB and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 1990;87: 9943-7.
15. Affres H, Perez J, Hagege J, et al. Desferrioxamine regulates tumor necrosis factor release in mesangial cells. Kidney Int 1991;39:822-30.
16. Clarkson AB, Saric M, Grady RW. Deferoxamine and eflornithine (DL-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1990;34:1833-5.
17. Weinberg GA. Iron chelators as therapeutic agents against Pneumocvstis carinii. Antimicrob Agents Chemother 1994;38:997-1003.
18. Kochan I. The role of iron in bacterial infections, with special consideration of host-tubercule bacillus interaction. Curr Top Microbiol Immunol 1973;60:1-30.
19. Youdim S. In vitro effect of iron salts and chelating agents on serum tuberculostasis. Am Rev Respir Dis 1969;99:925-31.
20. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996;87:3470-6.
21. Weinberg ED, Weinberg GA. The role of iron in infection. Curr Opin Infect Dis 1995;8:164-9.